<DOC>
	<DOCNO>NCT00116142</DOCNO>
	<brief_summary>This randomize study look benefit use docetaxel ( chemotherapy ) add one standard treatment ( radiation hormone ) men high-risk prostate cancer .</brief_summary>
	<brief_title>Hormone Suppression Radiation Therapy 6 Months With/Without Docetaxel High Risk Prostate Cancer</brief_title>
	<detailed_description>Radiation therapy plus six month hormone therapy one standard way treat men high-risk prostate cancer . In study , want see whether add chemotherapy drug docetaxel ( Taxotere ) make treatment effective . Docetaxel show benefit median survival give men become resistant hormonal therapy men metastatic prostate cancer ( spread area body ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>Biopsy proven prostate cancer Clinical Tumor Category T1b , T1c , T2a PSA great ( &gt; ) 10 Gleason score equal great 4+3=7 PSA velocity &gt; 2.0 ng/ml per year also eligible patient tumor category T2c , T3a , T3b , T4 per 2002 AJCC guideline . Any minor tertiary grade Gleason 5 ; Biopsy Proven Radiographic ( erMRI Seminal Vesicle Invasion ) ; Gleason = &gt; 3+4=7 50 % core positive Negative bone scan Lymph node assessment CT MR Adequate hematologic function ( Blood Counts ) Adequate liver function ( blood test ) ECOG performance Status 0 1 Peripheral neuropathy must = &lt; grade 1 PSA obtain within 3 month entry Prior history malignancy &lt; 5 year except cancer find `` insitu '' would likely impact patient 's life expectancy appropriate medical management . Prior pelvic radiation therapy Prior hormonal therapy ( 4 week prior enrollment allow ) Individuals unable tolerate lying still 5 10 minute Patients history severe hypersensitivity reaction docetaxel drug formulate polysorbate 90 .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Hormone Refractory</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Localized</keyword>
	<keyword>Locally Advanced</keyword>
	<keyword>Prostate Cancer - High Risk Localized Locally Advanced</keyword>
</DOC>